Abbott RA, Cox M, Markus H, Tomkins A. Diet, body size and micronutrient status in Parkinson’s disease. Eur J Clin Nutr 1992; 46:879-84.
Archibald FS, Tyree C. Manganese poisoning and the attack of trivalent manganese upon catecholamines. Arch Biochem Biophys 1987; 256(2):638-50.
Bender DA et al. Niacin depletion in Parkinsonian patients treated with L-dopa, benserazide and carbidopa. Clin Sci 1979; 56(1):89-93.
Ben-Shachar D, Youdim MB. Selectivity of melanized nigra-striatal dopamine neurons to degeneration in Parkinson’s disease may depend on iron-melanin interaction. J Neural Transm Suppl 1990; 29:251-8.
Baker AB. Treatment of paralysis agitans with vitamin B6 (pyridoxine hydrochloride). JAMA 1941;116:2484-7
Barbeau A. Manganese and extrapyramidal disorders (a critical review and tribute to Dr. George C. Cotzias). Neurotoxicology 1984; 5(1):13-35.
Beal MF. Mitochondria, oxidative damage, and inflammation in Parkinson's disease. Ann N Y Acad Sci. 2003;991:120-31.
Bell IR, Dalby P, Amend D, et al. Irritable bowel and specific food intolerances in Parkinson’s disease. Abstract. J Am Coll Nutr 1993; 12:615.
Birkmayer W, Birkmayer JGD. Iron, a new aid in the treatment of Parkinson patients. J Neural Transm 1986; 67(3-4):287-92.
Birkmayer JG, Birkmayer W. Improvement of disability and akinesia of patients with Parkinson’s disease by intravenous iron substitution. Ann Clin Lab Sci 1987; 17(1):32-5.
Birkmayer GJ, Birkmayer W. Stimulation of endogenous L-dopa biosynthesis - a new principle for the therapy of Parkinson’s disease. The clinical effect of nicotinamide adenine dinucleotide (NADH) and nicotinamide adenine dinucelotidephosphate (NADPH). Acta Neurol Scand Suppl 1989; 126:183-7.
Birkmayer W, Birkmayer GJ. Nicotinamidadenindinucleotide (NADH): The new approach in the therapy of Parkinson’s disease. Ann Clin Lab Sci 1989; 19(1):38-43.
Birkmayer W, Birkmayer JGD. Nicotinamid-adenine-dinucleotide (NADH): The new approach in the therapy of Parkinson’s disease. Ann Clin Sci 1989; 19:38-43.
Birkmayer W, Birkmayer GJ, Vrecko K, et al. The coenzyme nicotinamide adenine dinucleotide (NADH) improves the disability of parkinsonian patients. J Neurol Transm Park Dis Dement Sect 1989; 1(4):297-302.
Birkmayer W, Birkmayer JG, Vrecko K, Paltetta B. The clinical benefit of NADH as stimulator of endogenous L-dopa biosynthesis in Parkinsonian patients. Adv Neurol 1990; 53:545-9.
Birkmayer W, Birkmayer JGD, Vrecko K, et al. Nicotinamide Adenine Dinucleotide (NADH) as medication for Parkinson’s disease: Experience with 415 patients. New Trends in Clin Neuropharmacol 1990; 4:7-24.
Birkmayer JG, Vrecko C, Volc D, Birkmayer W. Nicotinamide adenine dinucleotide (NADH) -- a new therapeutic approach to Parkinson’s disease. Comparison of oral and parenteral application. Acta Neurol Scand 1993; 87:Suppl 146:32-5.
Black MJ, Brandt RB. Nicotinic acid or N-methyl nicotinamide prolongs elevated brain dopa and dopamine in L-dopa treatment. Biochem Med Metab Biol 1986; 36(2):244-51.
Bryant RC. Duration of illness and response to tryptophan in Parkinson’s disease. Letter. Arch Neurol 1980;37(10):677.
Charlene Latino. High-carbohydrate diet urged for Parkinson’s. Med Trib March 28, 1994:9.
Carter J et al. Amount and distribution of dietary protein affects clinical response to levodopa in Parkinson’s disease. Neurology 39:552-6, 1989.
Cerhan JR, Wallace RB, Folsom AR. Antioxidant intake and risk of Parkinson’s Disease in older women. Am J Epidemiol 139(11):S65, 1994.
Chen H, Zhang SM, Schwarzschild MA. Et al. Physical activity and the risk of Parkinson disease. Neurology. 2005;22;64(4):664-9.
Chen H, O'Reilly E, McCullough ML, et al. Consumption of Dairy Products and Risk of Parkinson's Disease. Am. J. Epidemiol. 2007 165: 998-1006.
Clayton P et al. Subacute combined degeneration of the cord, dementia and parkinsonism due to an inborn error of folate metabolism. J Neurol Neurosurg Psychiatry 49:920- 7, 1986.
Coimbra CG, Junqueira VB. High doses of riboflavin and the elimination of dietary red meat promote the recovery of some motor functions in Parkinson's disease patients. Braz J Med Biol Res 2003; 36(10): 1409-17.
Coppen A et al. Levodopa and L-tryptophan therapy in parkinsonism. Lancet i:654-7, 1972.
Corrigan FM, Wienburg CL, Shore RF, et al. Organochlorine insecticides in substantia nigra in Parkinson's disease. J Toxicol Environ Health 2000;59:229-34.
Costello S, Cockburn M, Bronstein J, et al. Parkinson's Disease and Residential Exposure to Maneb and Paraquat From Agricultural Applications in the Central Valley of California. Am. J. Epidemiol. 2009; 169: 919-26.
Demling J. L-dopa-induced psychoses and their treatment with L-tryptophan. Fortschr Med 1986; 104(17):360-2. (German).
de Rijk MC, Breteler MM, den Breeijen JH, et al. Dietary antioxidants and Parkinson disease. The Rotterdam Study. Arch Neurol 1997;54:762-5.
Dexter DT et al. Basal lipid peroxidation in substantia nigra is increased in Parkinson’s disease. J Neurochem 52(2):381-9, 1989.
Dexter DT et al. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson’s disease. J Neurochem 52(6):1830-6, 1989.
Dexter DT et al. Increased iron content in postmortem Parkinsonian brain. Letter. Lancet ii:1219-20, 1987.
Dexter DT et al. Lipid peroxidation as cause of nigral cell death in Parkinson’s disease.
Letter. Lancet ii:639-40, 1986.
Dexter DT et al. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson’s disease. J Neurochem 1989; 52(6):1830-6.
Donaldson J et al. Manganese neurotoxicity: A model for free-radical mediated neurodegeneration? Can J Physiol Pharmacol 1982; 60:1398-405.
Ebadi M. Oxidative stress and antioxidant therapy in Parkinson’s disease. Prog Neurobiol 1996;48:1-9.
Eriksson T et al. ‘On-off’ phenomenon in Parkinson’s disease: Relationship between dopa and other large neutral amino acids in plasma. Neurology 1988;38(8):1245-8.
Evatt ML, DeLong MR, Khazai N, et al. Prevalence of Vitamin D Insufficiency in Patients With Parkinson Disease and Alzheimer Disease. Arch Neurol. 2008;65(10):1348-1352.
Fahn S. The endogenous toxin hypothesis of the etiology of Parkinson’s disease and a pilot trial of high-dosage antioxidants in an attempt to slow the progression of the illness. Ann N Y Acad Sci 570:186-96, 1989.
Factor SA, Sanchez-Ramos JR, Weiner WJ. Vitamin E therapy in Parkinson’s disease. Adv Neurol 53:457-61, 1990.
Fahn S: An open trial of high-dosage antioxidants in early Parkinson's disease. Am J Clin Nutr 53(1) Suppl:380S-382S, 1991.
Fahn S. A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson’s disease. Ann Neurol 1992; 32:S128-32.
Florence TM, Stauber JL. Neurotoxicity of manganese. Letter. Lancet i:363, 1988.
Freye E, Hartung E. The potential use of thiamine in patients with cardiac insufficiency. Acta Vitaminol Enzymol 4:285-90, 1982 (observation of thiamine-neurotransmitter interaction).
Funfgeld EW, Baggen M, Nedwidek P, et al. Double-blind study with phosphatidylserine (PS) in parkinsonian patients with senile dementia of Alzheimer's type (SDAT). Prog Clin Biol Res 1989;317:1235-46.
Golbe LI et al. Case-control study of early life dietary factors in Parkinson’s disease. Arch Neurol 1988; 45:1350-3.
Golbe LI et al. Follow-up study of early-life protective and risk factors in Parkinson’s disease. Mov Disord 5(1):66-70, 1990.
Grimes JD et al. Prevention of progression of Parkinson’s disease with antioxidative therapy. Prog Neuropsychopharmacol Biol Psychiatry 12(2-3):165-72, 1988.
Growdon JH et al. Effects of oral L-tyrosine and homovanillic acid levels in patients with
Parkinson’s disease. Life Sci 30(10):827-32, 1982.
Growdon JH. An overview of phosphatidylcholine, in I Hanin, GB Ansell, Eds. Lecithin. New York, Plenum Publishing Co., 1987.
Götz ME et al. Oxidative stress: a role in the pathogenesis of Parkinson’s disease. J Neural Transm Suppl 29:241-9, 1990
Hellenbrand W et al. Diet and Parkinson's disease I: A possible role for the past intake of specific foods and food groups: Results from a self-administered food-frequency questionnaire in a case-control study. Neurology 47:636-43, 1996.
Hirsch EC et al. Iron and aluminum increase in the substantia nigra of patients with Parkinson’s disease: an X-ray microanalysis. J Neurochem 56(2):446-51, 1991.
Hornykiewicz O. Parkinson’s disease: From brain homogenate to treatment. Fed Proc 32:183-90, 1973.
Hsu TH et al. Effect of pyridoxine on levodopa metabolism in normal and Parkinsonian subjects. Proc Soc Exp Biol Med 143:577-81, 1973.
Jellinger K et al. Brain iron and ferritin in Parkinson’s and Alzheimer’s diseases. J Neural Transm Park Dis Dement Sect 2(4):327-40, 1990.
Jenner P. Oxidative damage in neurodegenerative disease. Lancet 344:796-8, 1994.
Jolliffe N. Clinical aspects of vitamin B deficiencies. Minn Med 23:542, 1940; Jolliffe N. Effects of vitamin B6 in paralysis agitans. Am Neurol Assoc Trans 66:54-9, 1940.
Juncos JL et al. Dietary influences on the antiparkinsonian response to levodopa. Arch Neurol 1987; 44(10):1003-5.
Kondo T et al. Effects of tyrosine administration on plasma biopterin in patients with juvenile parkinsonism and their relatives. Adv Neurol 1987; 45:217-22.
Lehmann J. Levodopa and depression in Parkinsonism. Lancet i:140, 1971.
Lehmann J. Tryptophan malabsorption in levodopa-treated parkinsonian patients. Acta Med Scand 194:181-9, 1973.
Lemoine P et al. L-tyrosine: a long-term treatment of Parkinson’s disease. C R Acad Sci [III] 309(2):43-7, 1989.
Logroscino G et al. Dietary lipids and antioxidants in Parkinson’s disease: a population-based, case-control study. Ann Neurol 39:89-94, 1996.
Mars H. Levodopa, carbidopa and pyridoxine in Parkinson disease. Metabolic interactions. Arch Neurol 30(6):444-7, 1974.
Mars H. Effect of chronic levodopa treatment on pyridoxine metabolism. Neurology 25(3):263-6, 1975.
Meco G et al: Parkinsonism after chronic exposure to the fungicide maneb (manganese ethylene-bis-dithiocarbamate). Scand J Work Environ Health 20(4):301-5,1994.
Mena I et al. Chronic manganese poisoning. Clinical picture and manganese turnover. Neurology 17:128-36, 1967.
Mena I, Cotzias GC. Protein intake and treatment of Parkinson’s disease with levodopa. N Engl J Med 292:181-4, 1975.
Mena MA, Pardo B, Paino CL, et al. Levodopa toxicity is foetal rat midbrain neurones in culture: modulation by ascorbic acid. Neuro Rep 4:438-40, 1993.
Meininger V et al: L-methionine treatment of Parkinson's disease: preliminary results (in French). Rev Neurol 138(4):297-303, 1982.
Miller EM et al. L-Tryptophan in the treatment of levodopa induced psychiatric disorders. Dis Nerv System 35:20-3, 1974.
Ngim CH, Devathasan G. Epidemiologic study on the association between body burden mercury level and idiopathic Parkinson’s disease. Neuroepidemiology 8(3):128-41, 1989.
Nutt JG et al. The “on-off” phenomenon in Parkinson’s disease. Relation to levodopa absorption and transport. N Engl J Med 310(8):483-8, 1984.
Parenti M et al. Manganese neurotoxicity: Effects of L-DOPA and pargyline treatments. Neurotoxicology 5(1):83-95, 1984.
Paré S, Barr SI, Ross SE. Effect of daytime protein restriction on nutrient intakes of free-living Parkinson’s disease patients. Am J Clin Nutr 55:701-7, 1992.
Park M, Ross GW, Petrovitch H et al. Consumption of milk and calcium in midlife and the future risk of Parkinson disease. Neurology 2005; 64(6):1047-1051.
Peers R. Fatty diet, mitochondria and Parkinson’s disease. N Z Med J 132, 1997.
Pfeiffer R, Ebadi M. On mechanisms of nullification of CNS effects of L-dopa by pyridoxine in Parkinsonian patients. J Neurochem 19:2175-81, 1972.
Pincus JH, Barry K. Protein redistribution diet restores motor function in patients with dopa-resistant ‘off’ periods. Neurology 38(3):481-3, 1988.
Pincus JH, Barry K. Influence of dietary protein on motor fluctuations in Parkinson’s disease. Arch Neurol 44(3):270-2, 1987.
Pincus JH, Barry KM. Dietary method for reducing fluctuations in Parkinson’s disease. Yale J Biol Med 60(2):133-7, 1987
Pincus JH, Barry KM. Plasma levels of amino acids correlate with motor fluctuations in parkinsonism. Arch Neurol 44(10):1006-9, 1987.
Playfer, J.R. Parkinson's disease. Postgraduate Medicine Journal, Vol. 73, May 1997, pp. 257-64.
Reilly DK et al. On-off effects in Parkinson’s disease: a controlled investigation of ascorbic acid therapy. Adv Neurol 37:51- 60, 1983.
Riederer P et al. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 52(2):515-20, 1989.
Riley D, Lang AE. Practical application of a low-protein diet for Parkinson’s disease. Neurology 38(7):1026-31, 1988.
Ritz B, Yu F. Parkinson's disease mortality and pesticide exposure in California 1984-1994. Int J Epidemiol 2000;29:323-9.
Rybicki BA et al: Parkinson's disease mortality and the industrial use of heavy metals in Michigan. Mov Disord 8(1):87-92, 1993.
Sacks W, Simpson GM. Ascorbic acid in levodopa therapy. Letter. Lancet i:527, 1975.
Sandyk R, Fisher H. L-tryptophan supplementation in Parkinson’s disease. Int J Neurosci 45(3- 4):215-9, 1989.
Shultz C.W et al. Effects of Coenzyme Q10 in Early Parkinson Disease Evidence of Slowing of the Functional Decline. Archives of Neurology 2002; 59:1541-1550
Sechi G, Deladda MG, Bua G, et al. Reduced intravenous glutathione in the treatment of early Parkinson’s disease. Prog Neuropsychopharmacol Biol Psychiatry 20:1159-70, 1996.
Semchuk KM et al: Parkinson's disease: a test of the multifactorial etiologic hypothesis. Neurology 43(6):1173-80, 1993.
Seidler A et al: Possible environmental, occupational and other etiologic factors for Parkinson's disease: a case-control study in Germany. Neurology 46(5):1275-84, 1996.
Schapira AHV, Cooper JM, Dexter D, et al. Mitochondrial complex I deficiency in Parkinson’s disease. J Neurochem 54:823-7, 1990.
Shoulson I. DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism. Ann Neurol 1998;44:S160-6.
Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 2002;59(10):1541-50.
Sian J, Dexter DT, Lees AJ, et al. Alterations in glutathione levels in Parkinson’s disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 36:348-55, 1994.
Singh RB, Niaz MA, Ghosh S, et al. Dietary intake and plasma levels of antioxidant vitamins in health and disease: a hospital-based case-control study. J Nutr Environ Med 5:235-42, 1995.
Smythies JR. Halsey JH. Treatment of Parkinson’s disease with L-methionine. South Med J
77:1577, 1984.
Sofic E et al. Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J Neurochem 56(3):978-82, 1991.
Sofic E, Lange KW, Jellinger K, et al. Reduced and oxidized glutathione in the Parkinsonian substantia nigra of patients with Parkinson’s disease. Neurosci Lett 142:128-30, 1992.
Steventon GB, Heafield MT, Waring RH, Williams AC. Xenobiotic metabolism in Parkinson’s disease. Neurology 39(7):883-7, 1989.
Stone S. Pyridoxine and thiamine therapy in disorders of the nervous system. Dis Nerv Sys 11(5):131-8, 1950.
Surtees R, Hyland K. L-3,4- dihydroxyphenylalanine (levodopa) lowers central nervous system S-adenosylmethionine concentrations in humans. J Neurol Neurosurg Psychiatry 53(7):569-72, 1990.
Tran N. L-Dopa and pyridoxine. Lancet ii:45-6, 1972.
Tsui J et al. The effect of dietary protein on the efficacy of L-dopa: A double-blind study. Neurology 39:549-52, 1989.
Uitti RJ et al. Regional metal concentrations in Parkinson’s disease, other chronic neurological diseases, and control brains. Can J Neurol Sci 16(3):310-4, 1989.
Uitti RJ et al: Parkinsonism induced by solvent abuse. Ann Neurol 35(5):616-9, 1994.
Vatassery GT, Fahn S, Kuskowski MA. Alpha tocopherol in CSF of subjects taking high-dose vitamin E in the DATATOP study. Parkinson Study Group. Neurology 1998;50:1900-2.
Vrecko K, Birkmayer JG, Krainz J. Stimulation of dopamine biosynthesis in cultured PC 12 phaeochromocytoma cells by the coenzyme nicotinamide adeninedinucleotide (NADH). J Neurol Transm Park Dis Dement Sect 5(2):147-56, 1993.
Waring RH, Steventon GB, Sturman SG, et al. S-methylation in motorneuron disease and Parkinson’s disease. Lancet ii:356-7, 1989.
Yahr MD et al. Pyridoxine, DOPA, and Parkinsonism. Adv Biochem Psychopharmacol 4:185-94, 1972.
Yamada M et al. Chronic manganese poisoning: A neuropathological study with determination of manganese distribution in the brain. Acta Neuropathol (Berl) 70(3-4):273-8, 1986.
Yamaguchi T et al. Effects of tyrosine administration on serum biopterin in normal controls and patients with Parkinson’s disease. Science 219:75-7, 1983.
Yapa S. Detection of subclinical ascorbate deficiency in early Parkinson’s disease. Public Health 106:393-5, 1992.
Yasui M et al. Magnesium-related neurological disorders, in Mineral and Metal Neurotoxicology. CRC Press, 1997:219-26.
Youdim MB et al. Is Parkinson’s disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration? Acta Neurol Scand Suppl 126:47-54, 1989.
Youdim MB et al. The role of monamine oxidase, iron-melanin interaction, and intracellular calcium in Parkinson’s disease. J Neural Transm Suppl 32:239-48, 1990.
Youdim MB et al. The role of iron in the basal ganglion. Adv Neurol 1990; 53:155-62.
Youdim KA, Joseph JA. A possible emerging role of phytochemicals in improving age-related neurological dysfunctions: a multiplicity of effects. Free Radic Biol Med 2001;30(6):583-94.
Zayed J et al. Environmental factors in the etiology of Parkinson’s disease. Can J Neurol Sci 1990;17(3):286-91.
